Correction
After the publication of this work [1], we noted that owing to an inadvertent mistake, the description of the chemotherapy schedule shown in the Methods was different from that shown in the Abstract and the duration of S-1 treatment in the initial chemoradiotherapy was inadequately described in Figure 1. Therefore, Methods and Figure 1 were modified accordingly.
Figure 1.

Chemoradiotherapy consisted of combination chemotherapy with S-1, biweekly cisplatin, and fractionated radiation therapy.
In the “Chemoradiotherapy” section in the Methods, the 1st and 3rd paragraphs should read as follows:
“The chemoradiotherapy protocol consisted of administration of S-1 plus biweekly cisplatin and radiation (Figure 1). The initial chemoradiotherapy schedule was for 6 weeks: S-1 was orally administered twice daily from the evening of day 1 to the morning of day 15, and the total dose was based on the patient’s body surface area (BSA), as follows: <1.25 m2, 80 mg; 1.25–1.5 m2, 100 mg; and >1.5 m2, 120 mg. An escalating dose of cisplatin was administered by infusion over 1 h on days 1 and 15 without infusional hydration. The starting dose (level 1) of cisplatin was 15 mg/m2, the second dose (level 2) was 20 mg/m2, and the third dose (level 3) was 25 mg/m2.”
“After initial chemoradiotherapy, one cycle of combination chemotherapy with S-1 plus biweekly cisplatin was delivered. This consisted of 42 days of S-1 administered from the evening of day 1 to the morning of day 29 and of cisplatin administered on days 1, 15, and 29.”In “Figure 1,” based on the description in the manuscript, the duration of S-1 treatment in the initial chemoradiotherapy was revised to 1–15 days from 1–22 days (Figure 1).
Contributor Information
Satoru Matsuda, Email: s.matsuda1983@gmail.com.
Tsunehiro Takahashi, Email: surgeontsune@yahoo.co.jp.
Junichi Fukada, Email: fukada@rad.med.keio.ac.jp.
Kazumasa Fukuda, Email: fukudak@z6.keio.jp.
Hirofumi Kawakubo, Email: hkawakubo@z3.keio.jp.
Yoshiro Saikawa, Email: saiky@z8.keio.jp.
Osamu Kawaguchi, Email: kawaguti@rad.med.keio.ac.jp.
Hiroya Takeuchi, Email: htakeuchi@a6.keio.jp.
Naoyuki Shigematsu, Email: shige@rad.med.keio.ac.jp.
Yuko Kitagawa, Email: kitagawa@a3.keio.jp.
References
- Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04. Radiat Oncol. 2014;9:9. doi: 10.1186/1748-717X-9-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
